49,50 Our in vivo assessments with the orallybioavailable SMARCA2/4 PROTAC degrader, AU-24118, demonstrated a favorabletolerability profile alongside significant anti-tumor efficacy in multiple SCLC-Pand MM preclinical models. This evidence concerns the gene SMARCA2 and neoplasm.